Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088114 · ClinicalTrials.gov registry record · Phase 1
STA-4783 and Paclitaxel for Treatment of Solid Tumors
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00088114: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00088114 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088114, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, toxicity and maximum tolerated dose of single doses of STA-4783/paclitaxel in combination when administered intravenously to patients with refractory cancer. To determine the pharmacokinetics of STA-4783 and paclitaxel when co-administered. To assess the anti-tumor activity of STA-4783 and paclitaxel when co-administered.
Interventions
- DRUG STA-4783/paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088114
The ClinicalTrials.gov registry entry for NCT00088114 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-4783/paclitaxel is the first listed.
NCT00088114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088114 about?
NCT00088114 is a clinical study titled "STA-4783 and Paclitaxel for Treatment of Solid Tumors". The purpose of this study is to determine the safety, toxicity and maximum tolerated dose of single doses of STA-4783/paclitaxel in combination when administered intravenously to patients with refractory cancer. To determine the pharmacokinetics of STA-4783 and paclitaxel when co-administered. To a...
What is the current status of trial NCT00088114?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2003-01. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00088114?
The interventions under investigation include: STA-4783/paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00088114?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.